👤 B Dranka

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
2
Articles
2
Name variants
Also published as: B.P. Dranka
articles

OXPHOS-targeting drugs in oncology: New perspectives

TA Kalyanaraman, N Daver, M Mahendra +242 more · 2023 · Expert opinion on therapeutic targets · Taylor & Francis · added 2026-04-20
TA Kalyanaraman, N Daver, M Mahendra, X Zhang, CV Dang, TM Ashton, WG McKenna, LA Kunz-Schughart, Y Xu, D Xue, A Bankhead, M Huang, CR Myers, Y Wang, B Kalyanaraman, SK Biswas, RAJ Smith, CM Porteous, AM Gane, MP Murphy, RC Hartley, E Fokas, M Benej, X Hong, S Vibhute, M Nishida, N Yamashita, T Ogawa, K Chandran, D Aggarwal, RQ Migrino, D Graham, NN Huynh, CA Hamilton, T Capeloa, J Krzystyniak, D d’Hose, JA Van de Velde, AC Rodriguez, NG Yoon, H Lee, SY Kim, S Yoshida, S Tsutsumi, G Muhlebach, A Rasola, L Neckers, D Picard, G Cheng, H Karoui, M Hardy, F Weinberg, R Hamanaka, WW Wheaton, B Fink, L Coppey, E Davidson, EM Gottwald, M Duss, M Bugarski, J Pan, Y Lee, JR Molina, Y Sun, M Protopopova, J Zielonka, M AbuEid, DM McAllister, L McOlash, IK Srivastava, H Rottenberg, AB Vaidya, PD Radloff, J Philipps, M Nkeyi, W Hughes, G Leoung, F Kramer, CD Freeman, NE Klutman, KC Lamp, A Darade, S Pathak, S Sharma, R Dixon, AL Pozniak, HM Watt, GL Nixon, DM Moss, AE Shone, M Fry, M Pudney, MW Mather, E Darrouzet, M Valkova-Valchanova, M Fiorillo, R Lamb, HB Tanowitz, M Xiang, H Kim, VT Ho, N Gupta, SK Srivastava, S Tian, H Chen, W Tan, D Xiong, P Topchyan, RM Loftus, DK Finlay, G Andrejeva, JC Rathmell, X Li, M Wenes, P Romero, T Gaber, C Strehl, F Buttgereit, A Tasdogan, JM Ubellacker, SJ Morrison, B Faubert, V Ramesh, Q Zhang, LP Burton, G Deng, CD Yanes, SR Lord, AL Harris, ME McGuinness, RL Talbert, H Zhao, KD Swanson, B Zheng, L Di Magno, S Manni, F Di Pastena, SR Veiga, X Ge, CA Mercer, R Masoud, G Reyes-Castellanos, S Lac, F Janku, SH Beom, YW Moon, O Ouari, KA Boyle, J Van Wickle, RB Hill, RF Keyes, D McAllister, Z Bielcikova, J Stursa, L Krizova, K Rohlenova, K Sachaphibulkij, KER Hollinshead, SJ Parker, VV Eapen, S Stemberkova-Hubackova, R Zobalova, M Dubisova, CA Reddy, V Somepalli, T Golakoti, S Jayakumar, RS Patwardhan, D Pal, A Mattarei, M Romio, A Managò, RK Pathak, S Marrache, DA Harn, DR Boulware, MF Pullen, AS Bangdiwala, S Crunkhorn, LD Zorova, VA Popkov, EY Plotnikov, J Joseph, A Sikora, L Dong, J Neuzil, A Solmonson, RJ DeBerardinis, V Gouirand, F Guillaumond, S Vasseur, GM Fischer, A Jalali, DA Kircher, VS LeBleu, JT O’Connell, KN Gonzalez Herrera, JH Park, S Vithayathil, S Kumar, F Sotgia, D Whitaker-Menezes, UE Martinez-Outschoorn, CR Bartman, DR Weilandt, Y Shen, YG Najjar, AV Menk, C Sander, AR Jaiswal, AJ Liu, S Pudakalakatti, MJ McManus, JL Franklin, RA Smith, B Mathieu, L Mignion, M Skwarski, DR McGowan, E Belcher, M Zielonka, B Dranka, HR Bridges, JG Fedor, JN Blaza, A Naguib, G Mathew, CR Reczek, SE Weinberg, BD Singer, EM Steinert, Z Zhao, Y Mei, Z Wang, K Vasan, M Werner, NS Chandel, EM De Francesco, B Ózsvári, S Izreig, A Gariepy, I Kaymak, D Kolb, N Kolishetti, B Surnar Show less
Introduction: Drugs targeting mitochondria are emerging as promising antitumor therapeutics in preclinical models. However, a few of these drugs have shown clinical toxicity. Developing mitochondria- Show more
Introduction: Drugs targeting mitochondria are emerging as promising antitumor therapeutics in preclinical models. However, a few of these drugs have shown clinical toxicity. Developing mitochondria-targeted modified natural compounds and US FDA-approved drugs with increased therapeutic index in cancer is discussed as an alternative strategy. Areas Covered: Triphenylphosphonium cation (TPP + )-based drugs selectively accumulate in the mitochondria of cancer cells due to their increased negative membrane potential, target the oxidative phosphorylation proteins, inhibit mitochondrial respiration, and inhibit tumor proliferation. TPP + -based drugs exert minimal toxic side effects in rodents and humans. These drugs can sensitize radiation and immunotherapies. Expert Opinion: TPP + -based drugs targeting the tumor mitochondrial electron transport chain are a new class of oxidative phosphorylation inhibitors with varying antiproliferative and antimetastatic potencies. Some of these TPP + -based agents, which are synthesized from naturally occurring molecules and FDA-approved drugs, have been tested in mice and did not show notable toxicity, including neurotoxicity, when used at doses under the maximally tolerated dose. Thus, more effort should be directed toward the clinical translation of TPP + -based OXPHOS-inhibiting drugs in cancer prevention and treatment. Show less
no PDF DOI: 10.1080/14728222.2023.2261631
anticancer mitochondria synthesis

Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer

Y. Park, P. Xu, D.M. Parkin +324 more · 2022 · Biomedicines · MDPI · added 2026-04-20
Y. Park, P. Xu, D.M. Parkin, F. Bray, J. Ferlay, P. Pisani, N. Andre, W. Schmiegel, B. Gustavsson, G. Carlsson, D. Machover, N. Petrelli, A. Roth, H. Schmoll, K. Tveit, F. Gibson, G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder, S. Sarkar, L. Bao, S. Hazari, S. Mehra, D. Kaushal, K. Moroz, S. Dash, Z. Yuan, X. Shi, Y. Qi, T. Jia, X. Yuan, Y. Zou, C. Liu, H. Yu, Y. Yuan, X. He, A.K. Pandurangan, D. Chao, W. Jiao, C. Yin, N. Jianyun, C. Ceshi, A. Guerrero-Zotano, I.A. Mayer, C.L. Arteaga, C. Han, G. Xing, M. Zhang, M. Zhong, Z. Han, C. He, X. Liu, Z. Zou, T. Tao, H. Li, X. Zhu, D.D. Sarbassov, S.M. Ali, D.M. Sabatini, D. Heras-Sandoval, J.M. Pérez-Rojas, J. Hernández-Damián, J. Pedraza-Chaverri, J. Roper, M.P. Richardson, W.V. Wang, L.G. Richard, W. Chen, E.M. Coffee, M.J. Sinnamon, L. Lee, P. Chen, R.T. Bronson, Y. Kondo, T. Kanzawa, R. Sawaya, S. Kondo, W. Li, Y. Zhou, J. Yang, H. Zhang, P. Zheng, Z. Wang, N. Wang, P. Liu, X. Xie, D. Zhang, W. Wang, X. Sun, D. Xu, C. Wang, Q. Zhang, H. Wang, W. Luo, Y. Chen, H. Chen, Z. Cao, Y. Yang, S. Yu, Y. Li, J. Huang, L. Xiong, S. Lei, C. Peng, M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, D.H. Suh, M.A. Kim, H. Kim, M. Kim, H.S. Kim, H.H. Chung, Y. Kim, Y.S. Song, J. Peng, Y. Cui, S. Xu, X. Wu, Y. Huang, W. Zhou, S. Wang, Z. Fu, H. Xie, G. Wang, Y. Yu, Y.Z. Wang, P.H. Yin, K. Xu, H. Bleiberg, P. Perego, J. Robert, W. Lian, M. Li, R.N. Seetharam, A. Sood, S. Goel, E. Martinez-Balibrea, A. Martínez-Cardús, A. Ginés, V. Ruiz de Porras, C. Moutinho, L. Layos, J.L. Manzano, C. Bugés, S. Bystrup, M. Esteller, P. Noordhuis, A.C. Laan, K. Van de Born, R.J. Honeywell, G.J. Peters, W. Sun, Y. Ge, J. Cui, B. Liu, W. Lu, M. Ma, Q. Yan, W. He, Y. Hu, L. Xia, W. Hou, J. Chai, H. Guo, J. Yu, S.H. Bae, J.H. Park, H.G. Choi, S.H. Kim, H.Y. Yoo, S.Y. Park, S.Y. Chang, G. Meyer, A. Czompa, C. Reboul, E. Stepania, A. Czegledi, I. Bak, G. Balla, J. Balla, A. Tosaki, I. Lekli, W. Cao, J. Li, K. Yang, D. Cao, I. Tanida, T. Ueno, E. Kominami, J.M. Woynarowski, S. Faivre, M.C. Herzig, B. Arnett, W.G. Chapman, A.V. Trevino, E. Raymond, S.G. Chaney, A. Vaisman, M. Varchenko, R. Teng, J. Zhou, B. Seifer, J. Shen, L. Wang, H.R. Kang, C.K. Jeon, S. Lim, J.I. Barrasa, A. Santiago-Gómez, N. Olmo, M.A. Lizarbe, J. Turnay, A. Derjuga, C. Richard, M. Crosato, P.S. Wright, L. Chalifour, J. Valdez, A. Barraso, H.A. Crissman, W. Nishioka, E.M. Bradbury, Q. Shi, S. Li, L. Jin, H. Lai, Y. Wu, Z. Cai, M. Zhu, Q. Li, C.W. Yao, K.A. Kang, M.J. Piao, Y.S. Ryu, P.M.D.J. Fernando, M.C. Oh, J.E. Park, K. Shilnikova, S.-Y. Na, S.U. Jeong, Y. Zhao, X. Hu, Y. Liu, S. Dong, Z. Wen, S. Zhang, Q. Huang, M. Shi, V.G.A. Arciuch, M.A. Russo, K.S. Kang, A.D. Cristofano, L. Vucicevic, M. Misirkic, J. Kristina, U. Vilimanovich, E. Sudar, E. Isenovic, M. Prica, L. Harhaji-Trajkovic, T. Kravic-Stevovic, B. Vladimir, S. Lee, W. Yang, D.K. Kim, M. Shin, K.U. Choi, D.S. Suh, Y.H. Kim, T.-H. Hwang, J.H. Kim, C. Wu, Y. Chao, S. Shiah, W. Lin, M. Mouradian, K.D. Kikawa, B.P. Dranka, S.M. Komas, B. Kalyanaraman, R.S. Pardini, F. Gharibpoor, S.K. Zonouzi, S. Razi, H. Rezaei, Z. Yao, F. Xie, Z. Liang, W. Xu, H. Zhou, L.-H. Qu, D. Catanzaro, D. Gabbia, V. Cocetta, M. Biagi, E. Ragazzi, M. Montopoli, M. Carrara, X. Cao, L. Fang, S. Gibbs, Z. Dai, P. Wen, X. Zheng, W. Sadee, D. Sun, E.E. Mendoza, M.G. Pocceschi, X. Kong, D.B. Leeper, J. Caro, K.H. Limesand, R. Burd, E. Domenech, C. Maestre, L. Esteban-Martínez, D. Partida, R. Pascual, G. Fernandez-Miranda, E. Seco, R. Campos-Olivas, M. Perez, D. Megias Show less
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well known. In Show more
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well known. In this study, oxaliplatin-resistant (OR) colorectal cancer (CRC) cells of HCT116, HT29, SW480 and SW620 were established by gradually increasing the drug concentration to 2.5 μM. The inhibitory concentrations of cell growth by 50% (IC 50 ) of oxaliplatin were 4.40–12.7-fold significantly higher in OR CRC cells as compared to their respective parental (PT) CRC cells. Phospho-Akt and phospho-mammalian target of rapamycin (mTOR) decreased in PT CRC cells but was overexpressed in OR CRC cells in response to oxaliplatin. In addition, an oxaliplatin-mediated decrease in phospho-AMP-activated protein kinase (AMPK) in PT CRC cells induced autophagy. Contrastingly, an increased phospho-AMPK in OR CRC cells was accompanied by a decrease in LC3B, further inducing the activity of glycolytic enzymes, such as glucose transporter 1 (GLUT1), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) and phosphofructokinase 1 (PFK1), to mediate cell survival. Inhibition of AMPK in OR CRC cells induced autophagy through inactivation of Akt/mTOR pathway and a decrease in GLUT1, PFKFB3, and PFK1. Collectively, targeting AMPK may provide solutions to overcome chemoresistance in OR CRC cells and restore chemosensitivity to anticancer drugs. Show less
đź“„ PDF DOI: 10.3390/biomedicines10112690
Pt amino-acid anticancer